Compare KRUS & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | CUVL |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Restaurants | Miscellaneous |
| Sector | Consumer Discretionary | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.1M | 374.2M |
| IPO Year | 2019 | 2004 |
| Metric | KRUS | CUVL |
|---|---|---|
| Price | $23.20 | $4.80 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $43.86 | N/A |
| AVG Volume (30 Days) | ★ 297.5K | 5.5K |
| Earning Date | 01-06-2027 | 08-27-2026 |
| Dividend Yield | N/A | ★ 0.59% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $328,276,000.00 | N/A |
| Revenue This Year | $15.09 | $0.47 |
| Revenue Next Year | $17.22 | $6.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.10 | N/A |
| 52 Week Low | $23.47 | $4.81 |
| 52 Week High | $80.84 | $8.20 |
| Indicator | KRUS | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 28.55 | 34.70 |
| Support Level | N/A | N/A |
| Resistance Level | $59.30 | $6.00 |
| Average True Range (ATR) | 2.18 | 0.23 |
| MACD | -0.66 | 0.01 |
| Stochastic Oscillator | 0.03 | 0.76 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.